Daniel O'Day, Sandra Horning, Michael Varney

Following Roche's successful tender offer for a majority of Foundation Medicine shares, Daniel O'Day, Sandra Horning, and Michael Varney have joined Foundation Medicine's board of directors.

O’Day is the chief operating officer of the Roche Pharmaceuticals division and a member of the Roche corporate executive committee, Horning is the global head of product development and chief medical officer for Roche's Genentech, and Varney is the head of Genentech research and early development.

The three new directors are joining five continuing directors: Foundation Medicine CEO Michael Pellini; Alexis Borisy, who will remain the board's chairman; Evan Jones; David Schenkein; and Krishna Yeshwant.